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The 2019 published NICE abortion care guidance (NG140) recommends that antibiotic prophylaxis is 
offered to women who are having a surgical abortion and, when using doxycycline, a 100mg twice a 
day for three days should be considered. The rationale to the recommendation states “a three-day 
course because this may be as effective and adherence is likely to be better with a shorter 
outcome”. This is a shorter duration than that presented as part of the consultation. Originally “the 
committee agreed that 7 days of doxycycline should be considered as it would be sufficient to treat 
sexually transmitted infections (STIs), if present. Further, there was expert knowledge that there is 
no evidence of increased antimicrobial resistance (AMR) with 7 days, compared with 3 days, of 
treatment. This is also consistent with recommendations from BASHH 2018 for treating 
Chlamydia.”[1]  
 
The evidence review concluded “RCT evidence showed there was no clinically important difference 
between the rate of adherence to antibiotics in the 3 day doxycycline antibiotic prophylaxis group 
and the 7 day doxycycline antibiotic prophylaxis group”. Additionally the “RCT evidence did not 
detect a clinically important difference in the rates of vomiting...No evidence was found for nausea.” 
Therefore the rationale for reducing the recommendation to three days cannot be based on 
improved adherence, side effect profile. 
Only one randomised controlled trial (RCT),[2] was identified using their search criteria to  answer 
the question “What is the optimal antibiotic prophylaxis regimen for women who are having a 
surgical termination of pregnancy?”. The study concluded that “Shortening oral doxycycline 
prophylaxis from 7 to 3 days had no adverse effect on the incidence of post-abortion infection”. Given 
that 1)  63% of women with chlamydia will develop pelvic inflammatory disease (PID) PID following 
surgical termination of pregnancy (TOP),[3] 2) seven days treatment is required to successfully treat 
Chlamydia[1] and 3) in the UK chlamydia is common in women having an abortion (5-7.6%),[4, 5]  
how can the conclusion of the expert review group be correct. We argue that it is because the panel 
failed to consider that the population studied by Litchenberg et al. is not representative of the 
majority of women undergoing TOP in the UK [2]. The authors state that STIs were uncommon in 
their population, women had a mean age 26.6yrs (chlamydia is associated with age <25 yrs)[1], they 
had a low incidence of post abortion infection and they did not test for chlamydia as part of the 
study.[2] As  chlamydia was uncommon we cannot be confident that this study would detect a 
difference in post abortion infection rates between the three day and seven day course in 
chlamydia-positive women. Therefore, it is inappropriate to generalise the findings of Litchenberg et 
al. to women undergoing TOP in the UK today. [2] 
The guideline also suggests using poorly defined criteria to identify women at risk of chlamydia 
“….unprotected sex and frequent change of and/or multiple sexual partners.”  The criteria of 
unprotected sex will have been met by all women presenting for an abortion and in women 
undergoing TOP partner change is not a risk factor for chlamydia in women undergoing TOP.[4] 
We therefore recommend that: “When using doxycycline for antibiotic prophylaxis in surgical 
abortion, oral doxycycline 100 mg twice a day for 7 days is recommended. A 3 day course can be 
considered if the woman is undergoing a vacuum aspiration and chlamydia infection has been 
excluded using a nucleic acid amplification test.” Women should also be advised that if they develop 
symptoms suggestive of PID they should seek medical care as early treatment reduces the risk of 
long term sequelae such as infertility. 
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